# BALAXI PHARMACEUTICALS (NSE: BALAXI) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BALAXI · Pivot · prices to 22 Oct 2026

BALAXI PHARMACEUTICALS (NSE: BALAXI) closed at ₹20.31 on 22 Oct 2026, down 4.65% on the day. With a market capitalisation of ₹112 Cr, it ranks 2598th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 78.1× trailing earnings, against a return on equity of 0.6% in FY26. Over the past year the share price has fallen 52.7%. Its 52-week range is ₹15.20 (27 Mar 2026) to ₹43.85 (4 Nov 2025); the last close is 53.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹81 Cr (+14.1% year on year) and net profit ₹1 Cr (+348.3%), on a consolidated basis. Promoters held 65.99% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹20.31 |
| Market cap | ₹112 Cr |
| P/E (trailing) | 78.1 |
| ROE | 0.6% (FY26) |
| ROCE | 3.1% (FY26) |
| Debt to equity | 0.22 |
| 52-week high | ₹43.85 (4 Nov 2025) |
| 52-week low | ₹15.20 (27 Mar 2026) |
| 1-year return | −52.7% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹81 Cr | +14.1% | ₹1 Cr | +348.3% | ₹0.24 |
| Q4 FY26 | ₹71 Cr | −7.3% | ₹1 Cr | −92.9% | ₹0.11 |
| Q3 FY26 | ₹73 Cr | −1.0% | ₹0 Cr | −94.2% | ₹0.06 |
| Q2 FY26 | ₹56 Cr | −27.4% | ₹0 Cr | −95.4% | ₹0.04 |
| Q1 FY26 | ₹71 Cr | +7.8% | ₹0 Cr | −95.5% | ₹0.05 |
| Q4 FY25 | ₹76 Cr | +27.5% | ₹9 Cr | −21.0% | ₹1.56 |
| Q3 FY25 | ₹73 Cr | +20.6% | ₹5 Cr | −60.6% | ₹0.97 |
| Q2 FY25 | ₹77 Cr | +41.4% | ₹5 Cr | −68.2% | ₹0.84 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹293 Cr | ₹25 Cr |
| FY24 | ₹241 Cr | −₹2 Cr |
| FY23 | ₹336 Cr | ₹46 Cr |
| FY22 | ₹279 Cr | ₹48 Cr |
| FY21 | ₹231 Cr | ₹38 Cr |
| FY20 | ₹46 Cr | ₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 65.99%
- Foreign institutions: 0.00%
- Domestic institutions: 2.56%
- Non-institutions: 31.45%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Krebs Biochemicals and Industries](https://app.pivotnow.in/stock/KREBSBIO) | ₹56.59 | ₹122 Cr | — | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹104.00 | ₹119 Cr | 10.1 | — |
| [Makers Labs](https://app.pivotnow.in/stock/MAKERSL) | ₹191.02 | ₹113 Cr | 48 | — |
| [Pharmaids Pharm](https://app.pivotnow.in/stock/PHARMAID) | — | ₹113 Cr | — | — |
| [Alpa Laboratories](https://app.pivotnow.in/stock/ALPA) | ₹51.70 | ₹109 Cr | 7.3 | — |

## Questions and answers

### What is the share price of BALAXI PHARMACEUTICALS today?

BALAXI PHARMACEUTICALS (NSE: BALAXI) last closed at ₹20.31 on 22 Oct 2026. Its 52-week high is ₹43.85 and its 52-week low is ₹15.20.

### What is the market cap of BALAXI PHARMACEUTICALS?

BALAXI PHARMACEUTICALS's market capitalisation is ₹112 Cr (₹112 Cr) at the 22 Oct 2026 close, ranking 2598th among the NSE companies Pivot tracks.

### What is the P/E ratio of BALAXI PHARMACEUTICALS?

BALAXI PHARMACEUTICALS trades at a trailing P/E of 78.1. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 10.1.

### What is the ROE and ROCE of BALAXI PHARMACEUTICALS?

Return on equity was 0.6% in FY26 and return on capital employed was 3.1% in FY26 (consolidated figures).

### Is BALAXI PHARMACEUTICALS a debt-free company?

No. BALAXI PHARMACEUTICALS's debt-to-equity ratio was 0.22 in FY26, with total debt of ₹22 Cr.

### What were BALAXI PHARMACEUTICALS's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), BALAXI PHARMACEUTICALS reported revenue of ₹81 Cr, +14.1% year on year, and net profit of ₹1 Cr, +348.3% year on year.

### How has BALAXI PHARMACEUTICALS stock performed over the last year?

BALAXI PHARMACEUTICALS's share price has fallen 52.7% over the past year, −16.0% over three months and −13.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of BALAXI PHARMACEUTICALS?

As of 30 Jun 2026: promoters 65.99%, foreign institutions 0.00%, domestic institutions 2.56%, non-institutions 31.45%.

### Who are BALAXI PHARMACEUTICALS's competitors?

The listed Pharma & Healthcare companies closest to BALAXI PHARMACEUTICALS by market cap are Krebs Biochemicals and Industries, Godavari Drugs, Parnax Lab, Makers Labs, Pharmaids Pharm and Alpa Laboratories.

### Is BALAXI PHARMACEUTICALS a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out BALAXI PHARMACEUTICALS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BALAXI against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.